PHARMACEUTICALS
DHL Group goes boldly DHL Group is putting US $ 2.1bn behind its healthcare logistics ambitions, rolling out an expansion plan aimed at transforming how life sciences products are stored, shipped and delivered across the globe.
The investment will run until 2030 and marks a major chapter in the company’ s Strategy 2030 roadmap.
The goal is to reinforce DHL’ s supply chain services for the pharmaceutical, biopharma and medical devices sectors with upgraded cold chain capabilities, more high-tech storage, faster cross-border distribution and smarter digital visibility.
Pharmaceutical products often require tightly controlled environments – whether it is vaccines that need ultralow temperatures or sensitive biologics needing stable cooling during transit.
High-quality, integrated solutions DHL is pouring a large portion of its investment into building cross-divisional GPD-certified Pharma Hubs and increasing the capacity of temperature-controlled warehouses and delivery vehicles.
The plan also calls for expanding infrastructure to manage the complex requirements of fast-developing segments like cell and gene therapies, which demand ultralow temperatures for safe transport.
Oscar de Bok, CEO of DHL Supply Chain, says:“ We’ re building high-quality, integrated logistics solutions that are as
114 August 2025